Pharmacodynamic assessment of mycophenolic acid in a canine model
Langman, L.J.; Shapiro, A.M.; Lakey, J.R.; LeGatt, D.F.; Kneteman, N.M.; Yatscoff, R.W.
Transplantation Proceedings 28(2): 934-936
1996
ISSN/ISBN: 0041-1345 PMID: 8623469 Document Number: 456029
Document emailed within 1 workday
Related Documents
Chand, A.K.; Rout, D. 1995: Role of urokinase in the management of experimental intraventricular hemorrhage in canine model - Part 1 : canine intraventricular blood cast model Neurology India 41(2): 65-67Sweeney, M.J.; Hoffmann, D.H.; Poore, G.A. 1971: Possible in situ activation of mycophenolic acid by beta-glucuronidase Cancer Research 31(4): 477-478
Ohsugi, Y.; Suzuki, S.; Takagaki, Y. 1976: Antitumor and immunosuppressive effects of mycophenolic acid derivatives Cancer Research 36(8): 2923-2927
Pancheva, S.N.; Roeva, I.G.; Remichkova, M.G. 1997: Antiherpetic activity of acyclovir is potentiated by mycophenolic acid Acta Virologica 41(6): 357-358
Yu, Z.-C.; Chen, H.; Zhang, W.-X.; Zhou, P.-J.; Zhou, G.-W.; Chen, H.-Z. 2006: Pharmacokinetics of mycophenolic acid in Chinese patients with liver transplant Yao Xue Xue Bao 41(12): 1157-1160
Martiny, D.; Macours, P.; Frédéric Cotton; Thiry, P.; Béatrice Gulbis 2010: Reliability of Mycophenolic Acid Monitoring by an Enzyme Multiplied Immunoassay Technique Clinical Laboratory 56(7-8): 345-353
Merkel, U.; Lindner, S.; Vollandt, R.; Sperschneider, H.; Balogh, A. 2005: Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients International Journal of Clinical Pharmacology and Therapeutics 43(8): 379-388
Zeevi, A.; Woan, M.; Yao, G.Z.; Venkataramanan, R.; Todo, S.; Starzl, T.E.; Duquesnoy, R.J. 1991: Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin Transplantation Proceedings 23(6): 2928-2930
Iwasaki, K.; Miyazaki, Y.; Teramura, Y.; Kawamura, A.; Tozuka, Z.; Hata, T.; Undre, N. 1996: Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid Research Communications in Molecular Pathology and Pharmacology 94(3): 251-257
Julasareekul, W.; Eiam-Ong, S.; Bejraputra, O.; Seublinvong, T. 2003: Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram/day) of mycophenolate mofetil Journal of the Medical Association of Thailand 86(8): 766-771
Jackson, C.V.; Crowe, V.G.; Frank, J.D.; Wilson, H.C.; Coffman, W.J.; Utterback, B.G.; Jakubowski, J.A.; Smith, G.F. 1992: Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis Journal of Pharmacology and Experimental Therapeutics 261(2): 546-552
Lin, B.; Zhu, Y-chun.; Lu, Y-ping. 2009: Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil Zhonghua Yi Xue Za Zhi 89(4): 251-253
Lee, H.J.; Pawlak, K.; Nguyen, B.T.; Robins, R.K.; Sadée, W. 1985: Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture Cancer Research 45(11 Part 1): 5512-5520
Mandema, J.W.; Wada, D.R. 1995: Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat Journal of Pharmacology and Experimental Therapeutics 275(3): 1185-1194
Salmon, J.; Levêque, D.; Peter, J.D.; Cavalier, A.; Elkhaïli, H.; Salmon, Y.; Kaltenbach, G.; Monteil, H.; Jehl, F. 1996: Model of a miniature pig catheterized for pharmacokinetic and pharmacodynamic studies of anti-infective agents Pathologie-Biologie 44(5): 375-378
Munck, J.N.; Riggi, M.; Rougier, P.; Chabot, G.G.; Ramirez, L.H.; Zhao, Z.; Bognel, C.; Ardouin, P.; Herait, P.; Gouyette, A. 1993: Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model Cancer Research 53(7): 1550-1554
Cheng, H.H.; Kuo, S.C.; Lin, W.C. 1999: Pharmacodynamic and pharmacokinetic studies of anthraquinone 2-carboxylic acid on passive cutaneous anaphylaxis in rats Research Communications in Molecular Pathology and Pharmacology 105(1-2): 97-103
Elkhaïli, H.; Pompei, D.; Peter, J.D.; Linger, L.; Salmon, J.; Levêque, D.; Niedergang, S.; Salmon, Y.; Thierry, R.C.; Monteil, H.; Jehl, F. 1997: In vivo pharmacokinetic of amikacin and its pharmacodynamic in combination with cefepime, cefpirome and meropenem in an in vitro/ex vivo micropig model Pathologie-Biologie 45(5): 347-356
Sangiorgi, M.; Cannata, D.; Moscatello, B. 1971: An investigation of the preventive action of sodium nitrite, nicotinic acid, papaverine, and aminophylline on angina of effort. Comparative pharmacodynamic study Cor et Vasa 13(4): 244-250
Gore, T.C.; Lakshmanan, N.; Duncan, K.L.; Coyne, M.J.; Lum, M.A.; Sterner, F.J. 2005: Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus Veterinary Therapeutics: Research in Applied Veterinary Medicine 6(1): 5-14